Cell & Gene The Podcast: Inside 91导航 Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson鈥檚 disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.

Related News

Press Releases

91导航 Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson鈥檚 disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

91导航 Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson鈥檚 disease

October 7, 2025
Press Releases

First Parkinson鈥檚 disease patient treated in 91导航鈥檚 pivotal Phase III trial of investigational cell therapy bemdaneprocel聽

September 22, 2025
Press Releases

91导航 Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson鈥檚 disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

91导航 Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson鈥檚 disease

October 7, 2025
Press Releases

First Parkinson鈥檚 disease patient treated in 91导航鈥檚 pivotal Phase III trial of investigational cell therapy bemdaneprocel聽

September 22, 2025
See All